Recent Report on Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016 is a new market research publication announced by Reportstack. This report provides an overview of the Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline landscape.

MRSA infections that are acquired by persons who have not been recently (within the past year) hospitalized or had a medical procedure (such as dialysis, surgery, catheters) are known as community-acquired MRSA (CA-MRSA) infections. Risk factors are hemodialysis, weakened immune system, admission to hospitals and wounds. Symptoms include skin rashes, fatigue, chest pain, fever and swelling. MRSA can be managed by the use of antibiotics and by maintaining hygienic conditions.

To access full report with TOC, please visit Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - Pipeline Review, H2 2016

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Methicillin-Resistant Staphylococcus aureus (MRSA) Infections – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 8, 10, 12, 72, 33 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 21 and 22 molecules, respectively.Methicillin-Resistant Staphylococcus aureus (MRSA) Infections.

Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- The pipeline guide reviews pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. 
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects. 
- The pipeline guide reviews latest news related to pipeline therapeutics for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Methicillin-Resistant Staphylococcus aureus (MRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies Mentioned

Absynth Biologics Limited Actelion Ltd Adenium Biotech ApS AIMM Therapeutics B.V. Alchemia Limited Allergan Plc AlphaMab Co., Ltd Alvogen Korea Co., Ltd. AmpliPhi Biosciences Corporation AnGes MG, Inc. Antibiotx ApS Aphios Corporation Aridis Pharmaceuticals LLC Arsanis, Inc. AstraZeneca Plc Atriva Therapeutics GmbH Bavarian Nordic A/S Bharat Biotech International Limited C3 Jian, Inc Cellceutix Corporation Cempra Inc Citius Pharmaceuticals, Inc. Common Pharma Inc ContraFect Corporation Crestone, Inc. Critical Outcome Technologies Inc CrystalGenomics, Inc. CSA Biotechnologies LLC Debiopharm International SA Dermala Inc DesignMedix, Inc. Destiny Pharma Limited Dong-A Socio Holdings Co. Ltd. e-Therapeutics Plc Emergent BioSolutions Inc. Ensol Biosciences Inc. Excelimmune, Inc. Galapagos NV GangaGen Inc. Gero Corp Helix BioMedix, Inc. Hsiri Therapeutics LLC Ildong Pharmaceutical Co., Ltd. Immupharma Plc iNtRON Biotechnology Inc. ioGenetics, Inc. Kyorin Pharmaceutical Co., Ltd. Lascco SA LegoChem Biosciences, Inc Lipocure Ltd. Madam Therapeutics B.V. Melinta Therapeutics, Inc Merck & Co., Inc. Microbiotix, Inc. MicuRx Pharmaceuticals, Inc. MorphoSys AG Motif Bio Plc Nabriva Therapeutics AG Nemus Bioscience, Inc. Novabiotics Limited NovaDigm Therapeutics, Inc. NovoBiotic Pharmaceuticals, LLC Omnia Molecular Ltd. Oragenics, Inc. Pfizer Inc. Phico Therapeutics Limited Procarta Biosystems Limited Prommune, Inc. Recce Pty Ltd Redx Pharma Plc Sarepta Therapeutics, Inc. Savara Inc. Sealife PHARMA GMBH Sentinella Pharmaceuticals, Inc. Sequoia Sciences Inc Soligenix, Inc. Sorrento Therapeutics Inc Taejoon Pharm Co., Ltd. TAXIS Pharmaceuticals, Inc. Telephus Medical LLC Tetraphase Pharmaceuticals Inc. TGV-Laboratories Theravance Biopharma Inc Trellis Bioscience, Inc. Valevia UK Limited VLP Biotech, Inc. Wintermute Biomedical LLC Wockhardt Limited XBiotech Inc Yungjin Pharm. Co., Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###